ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2825

Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis

Sanat Phatak, Smriti Chaurasia, Shravan Mishra, Ranjan Gupta, Amita Aggarwal and Ramnath Misra, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Urinary Biomarkers and lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: B cell Activating Factor of the TNF Family (BAFF) and A Proliferation Inducing Ligand (APRIL) help B cell activation, maintenance and plasma cell survival. Consequently, these facilitate production of pathogenic autoantibodies in SLE and lupus nephritis. B cells infiltration has been demonstrated in kidneys of patients with Lupus Nephritis (LN). Serum levels of BAFF and APRIL have shown inconsistent relationships with lupus disease activity. We evaluated urinary levels of BAFF and APRIL as a biomarker for LN.

Methods: Thirty-six patients with proliferative lupus nephritis (AN), 10 with active lupus without nephritis (AL) and 15 healthy controls (HC) were studied. APRIL and BAFF levels were measured in both serum and urine using ELISA. Urine levels were normalized to urinary creatinine excretion. Urine levels were correlated with conventional disease activity markers like SLEDAI, renal SLEDAI, and proteinuria. Levels were reassessed in 20 AN patients at 6 months, after treatment with cyclophosphamide.

Results: At baseline, urinary APRIL (uAPRIL) and BAFF (uBAFF) were significantly raised in AN patients as compared to controls. [Table1] uAPRIL but not uBAFF had correlation with renal SLEDAI in patients with AN. (r= 0.36, p<0.05). On ROC analysis, uBAFF (AUC 0.825) and uAPRIL (AUC 0.781)performed better than low C3, C4 and raised anti-dsDNA antibodies in differentiating AN and AL patients. The uBAFF and uAPRIL levels did not correlate with their serum levels suggesting in situ generation in the kidneys. On follow up uAPRIL levels reduced (125 pg/mg to 36 pg/mg, p<0.05). However uBAFF levels reduced only in 16 responders (158 to 67 pg/mg, p<0.05). Two of the 4 non-responders had increase in uBAFF levels.

Conclusion: uBAFF and uAPRIL are potential biomarkers of proliferative lupus nephritis. Table 1: Disease activity and BAFF, APRIL levels at baseline.

Parameter Lupus nephritis (n=36) Active non-renal lupus (n=10) Lupus, non nephritis
Age in years (median, range) 32 (19 – 59) 27 (23 – 36) 31 (19-50)
SLEDAI 2K (median, range) 18 (8-30) 9 (6-20) NA
Renal SLEDAI (median, range) 8 (4-16) 0 NA
Urine 24 hour protein- g/24 hours 4.9 (3.6) 0.31 (0.13)* NA
Normalized Urine BAFF (pg/mg)

240 (290)

60.9 (62)*

58 (101)*

Normalized Urine APRIL (pg/mg)

125 (116)

28.4 (20)*#

01 (05)*

Serum BAFF (ng/ml)

0.184 (0.26)

0.27 (0.20)

0.135(0.69)

Serum APRIL (ng/ml)

1.249 (0.72)

1.38 (0.53)

2.00 (1.74)

*p <0.05 compared to lupus nephritis, # p<0.05 compared to healthy control All values: mean with standard deviation NA: not applicable


Disclosure: S. Phatak, None; S. Chaurasia, None; S. Mishra, None; R. Gupta, None; A. Aggarwal, None; R. Misra, None.

To cite this abstract in AMA style:

Phatak S, Chaurasia S, Mishra S, Gupta R, Aggarwal A, Misra R. Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/urinary-baff-and-april-levels-potential-biomarkers-of-active-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-baff-and-april-levels-potential-biomarkers-of-active-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology